Oncological outcome after local treatment for early stage rectal cancer

dc.citation.issue1
dc.citation.volume36
dc.contributor.authorWitjes CDM
dc.contributor.authorPatel AS
dc.contributor.authorShenoy A
dc.contributor.authorBoyce S
dc.contributor.authorEast JE
dc.contributor.authorCunningham C
dc.coverage.spatialGermany
dc.date.accessioned2023-06-22T20:49:29Z
dc.date.available2022-01
dc.date.available2021-01-09
dc.date.available2023-06-22T20:49:29Z
dc.date.issued2022-01
dc.description(c) The Author/s
dc.description.abstractBACKGROUND: Treatment of early rectal cancer is evolving towards organ-preserving therapy which includes endoscopic resection and transanal approaches. We aimed to explore the role of local treatments such as endoscopic polypectomy (Endoscopic Mucosal Resection (EMR) or Endoscopic submucosal dissection (ESD)) and transanal endoscopic microsurgery/ transanal minimal invasive surgery (TEM/TAMIS) in patients who had early rectal cancer. We considered these outcomes alongside conventional major surgery using total mesorectal excision (TME) for early stage disease. METHODS: All patients identified at MDT with early stage rectal cancer at our institution between 2010 and 2019 were included. Long-term outcomes in terms of local recurrence, survival and procedure-specific morbidity were analysed. RESULTS: In total, 536 patients with rectal cancer were identified, of which 112 were included based on their pre-operative identification at the MDT on the basis that they had node-negative early rectal cancer. Among these, 30 patients (27%) had the lesion excised by flexible endoscopic polypectomy techniques (EMR/ESD), 67 (60%) underwent TEM/TAMIS and 15 (13%) had major surgery. There were no differences in patient demographics between the three groups except for TEM/TAMIS patients being more likely to be referred from another hospital (p < 0.001) and they were less active (WHO performance status p = 0.04). There were no significant differences in overall survival rates and cancer-specific survival between the three treatment groups. The 5-year overall survival rate for endoscopic polypectomy, TEM/TAMIS or major resection was 96% versus 90% and 88%, respectively (p = 0.89). The 5- year cancer-specific survival rate was 96%, versus 96% and 100%, respectively (p = 0.74). CONCLUSION: Endoscopic polypectomy by EMR/ESD is an appropriate local treatment for early stage rectal cancer in selected patients. It is possible to achieve good oncological outcomes with a polypectomy similar to TEM/TAMIS and major surgery; however, a multidisciplinary approach is necessary enabling close surveillance and the use of adjuvant radiotherapy.
dc.description.publication-statusPublished
dc.format.extent489 - 497
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/33544250
dc.identifier10.1007/s00464-021-08308-1
dc.identifier.citationSurg Endosc, 2022, 36 (1), pp. 489 - 497
dc.identifier.doi10.1007/s00464-021-08308-1
dc.identifier.eissn1432-2218
dc.identifier.elements-id440763
dc.identifier.harvestedMassey_Dark
dc.identifier.urihttps://hdl.handle.net/10179/18348
dc.languageeng
dc.publisherSpringer Science+Business Media, LLC
dc.relation.isPartOfSurg Endosc
dc.subjectEarly rectal cancer
dc.subjectLocal treatment
dc.subjectPolypectomy (EMR/ESD)
dc.subjectTAMIS
dc.subjectTEM
dc.subjectEndoscopic Mucosal Resection
dc.subjectHumans
dc.subjectNeoplasm Recurrence, Local
dc.subjectRadiotherapy, Adjuvant
dc.subjectRectal Neoplasms
dc.subjectRectum
dc.subjectTransanal Endoscopic Microsurgery
dc.subjectTreatment Outcome
dc.subject.anzsrc1103 Clinical Sciences
dc.titleOncological outcome after local treatment for early stage rectal cancer
dc.typeJournal article
pubs.notesNot known
pubs.organisational-group/Massey University
pubs.organisational-group/Massey University/College of Health
pubs.organisational-group/Massey University/College of Health/Research Centre for Hauora and Health
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
440763 PDF.pdf
Size:
791.36 KB
Format:
Adobe Portable Document Format
Description:
Collections